Engine banks $43m in one of the largest series A rounds in Singapore’s biotech space

Singapore- and Silicon Valley-based Engine Biosciences has raised S$57 million (US$43 million) in what it says is the largest series A funding for a biotech company in Singapore. The fundraise pushes Engine’s total amount raised to date to over US$52 million.

More funding details

• Lead investor: Polaris Partners
• Returning investors: 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest Bio Labs
• Stage: Series A

More company updates

• Engine Biosciences said it’s progressing its biology findings into drug discovery programs and plans to use the fresh capital to expand its portfolio of precision oncology therapeutics.
• The company also looks to prepare for its first clinical programs and further develop its NetMappr platform, which integrates machine learning into biological experiments and drug discovery.
• It plans to explore collaborations to apply its platform’s capabilities in discovering treatments for other disease areas as well.
• To date, Engine Biosciences said it has performed a number of large-scale computational and experimental cycles that have led to validated discoveries.

For more coverage of the company, head here. You can also click on the link below to view key details about the company, as well as its funding history.